Cassava Sciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Rhea-AI Summary

Cassava Sciences (NASDAQ: SAVA), a biotechnology company specializing in novel treatments for central nervous system (CNS) disorders, has announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference.

The company's President and CEO, Rick Barry, will deliver a corporate presentation on Monday, September 8, 2025, at 5 PM ET in New York City. The presentation will be available via webcast, with a replay accessible on Cassava's investor website for approximately 90 days after the event.

AUSTIN, Texas, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders, such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced management’s participation in the H.C. Wainwright 27^th Annual Global Investment Conference being held September 8 – 10, 2025 in New York City.

Rick Barry, President and Chief Executive Officer, will participate in-person at this corporate event.

Conference details are as follows:

H.C. Wainwright 27^th Annual Global Investment Conference
Format: Corporate Presentation
Date: Monday, September 8, 2025
Time: 5 PM ET
Webcast Link: Here

A replay of the webcast will be accessible on the Cassava Investor’s website for approximately 90 days following the event.

To request a meeting or for more details about the conference please reach out to your institutional contact.

About Cassava Sciences, Inc.

Cassava Sciences, Inc. (NASDAQ: SAVA), is a biotechnology company focused on developing novel, investigational treatments, including simufilam, for central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and potentially other indications. Simufilam is a proprietary, investigational oral small molecule believed to modulate activity of the filamin A protein, which regulates diverse aspects of neuronal development. The Company is based in Austin, Texas.

For more information, please visit: https://www.CassavaSciences.com

For More Information Contact:

Investors
Sandya von der Weid
svonderweid@lifesciadvisors.com

Company
Eric Schoen, Chief Financial Officer
(512) 501-2450
ESchoen@CassavaSciences.com
IR@cassavasciences.com

FAQ

When is Cassava Sciences (SAVA) presenting at the H.C. Wainwright Conference 2025?

Cassava Sciences will present on Monday, September 8, 2025, at 5 PM ET at the H.C. Wainwright Conference in New York City.

Who will represent Cassava Sciences (SAVA) at the H.C. Wainwright Conference?

Rick Barry, President and Chief Executive Officer of Cassava Sciences, will deliver the corporate presentation.

How can investors access Cassava Sciences' (SAVA) H.C. Wainwright Conference presentation?

The presentation will be available via webcast, with a replay accessible on Cassava's investor website for 90 days following the event.

What is Cassava Sciences' (SAVA) main business focus?

Cassava Sciences is a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders, such as Tuberous Sclerosis Complex (TSC)-related epilepsy.